Multicenter Clinical Evaluation of Modified Two-Tiered Testing Algorithms for Lyme Disease Using Zeus Scientific Commercial Assays

Modified two-tiered testing (MTTT) algorithms for Lyme disease (LD), which involve the sequential use of orthogonal enzyme immunoassays (EIAs) without immunoblotting, are acceptable alternatives to standard two-tiered testing (STTT; EIA followed by immunoblots) provided the EIAs have been FDA-cleare...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical microbiology Vol. 60; no. 5; p. e0252821
Main Authors: Sfeir, Maroun M, Meece, Jennifer K, Theel, Elitza S, Granger, Dane, Fritsche, Thomas R, Steere, Allen C, Branda, John A
Format: Journal Article
Language:English
Published: United States 18.05.2022
Subjects:
Algorithms
Animals
Antibodies, Bacterial
Borrelia burgdorferi
Fishes
Humans
Immunoglobulin M
Lyme Disease
Prospective Studies
Retrospective Studies
Sensitivity and Specificity
Serologic Tests
Lyme disease
Borrelia burgdorferi
diagnostics
Borrelia
immunodiagnostics
serology
ISSN:1098-660X, 1098-660X
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Modified two-tiered testing (MTTT) algorithms for Lyme disease (LD), which involve the sequential use of orthogonal enzyme immunoassays (EIAs) without immunoblotting, are acceptable alternatives to standard two-tiered testing (STTT; EIA followed by immunoblots) provided the EIAs have been FDA-cleared for this intended use. We evaluated four Zeus Scientific LD EIAs used in two distinct MTTT algorithms for FDA review. MTTT 1 used a VlsE1/pepC10 polyvalent EIA followed by a whole-cell sonicate (WCS) polyvalent EIA. MTTT 2 used the same first-tier EIA followed by separate IgM and IgG WCS EIAs. In a retrospective phase, we compared each MTTT algorithm to STTT using archived samples from LD patients or control subjects. In a prospective phase, we used the same algorithms to analyze consecutive excess samples submitted for routine LD serology to three clinical laboratories. For the retrospective phase, MTTTs 1 and 2 were more sensitive (56% and 74%) than STTT (41%;  ≤ 0.03) among 61 patients with acute erythema migrans (EM). In LD patients with neuroborreliosis, carditis, or arthritis (  75), sensitivity was comparable between algorithms (96 to 100%; = 1.0). Among 190 control subjects without past LD, all algorithms were highly and comparably specific (≥99%, = 0.48). For the prospective phase, (  2,932), positive percent-agreement (PPA), negative percent-agreement (NPA), and overall agreement of MTTT 1 with STTT were 93%, 97.7% and 97.4% (kappa 0.80). MTTT 2 yielded higher PPA (98%) but lower NPA (96.1%) and overall agreement (96.2%, kappa 0.74; all < 0.05). Compared with STTT, both MTTT algorithms provided increased sensitivity in EM patients, comparable sensitivity in later disease and non-inferior specificity.
AbstractList Modified two-tiered testing (MTTT) algorithms for Lyme disease (LD), which involve the sequential use of orthogonal enzyme immunoassays (EIAs) without immunoblotting, are acceptable alternatives to standard two-tiered testing (STTT; EIA followed by immunoblots) provided the EIAs have been FDA-cleared for this intended use. We evaluated four Zeus Scientific LD EIAs used in two distinct MTTT algorithms for FDA review. MTTT 1 used a VlsE1/pepC10 polyvalent EIA followed by a whole-cell sonicate (WCS) polyvalent EIA. MTTT 2 used the same first-tier EIA followed by separate IgM and IgG WCS EIAs. In a retrospective phase, we compared each MTTT algorithm to STTT using archived samples from LD patients or control subjects. In a prospective phase, we used the same algorithms to analyze consecutive excess samples submitted for routine LD serology to three clinical laboratories. For the retrospective phase, MTTTs 1 and 2 were more sensitive (56% and 74%) than STTT (41%;  ≤ 0.03) among 61 patients with acute erythema migrans (EM). In LD patients with neuroborreliosis, carditis, or arthritis (  75), sensitivity was comparable between algorithms (96 to 100%; = 1.0). Among 190 control subjects without past LD, all algorithms were highly and comparably specific (≥99%, = 0.48). For the prospective phase, (  2,932), positive percent-agreement (PPA), negative percent-agreement (NPA), and overall agreement of MTTT 1 with STTT were 93%, 97.7% and 97.4% (kappa 0.80). MTTT 2 yielded higher PPA (98%) but lower NPA (96.1%) and overall agreement (96.2%, kappa 0.74; all < 0.05). Compared with STTT, both MTTT algorithms provided increased sensitivity in EM patients, comparable sensitivity in later disease and non-inferior specificity.
Modified two-tiered testing (MTTT) algorithms for Lyme disease (LD), which involve the sequential use of orthogonal enzyme immunoassays (EIAs) without immunoblotting, are acceptable alternatives to standard two-tiered testing (STTT; EIA followed by immunoblots) provided the EIAs have been FDA-cleared for this intended use. We evaluated four Zeus Scientific LD EIAs used in two distinct MTTT algorithms for FDA review. MTTT 1 used a VlsE1/pepC10 polyvalent EIA followed by a whole-cell sonicate (WCS) polyvalent EIA. MTTT 2 used the same first-tier EIA followed by separate IgM and IgG WCS EIAs. In a retrospective phase, we compared each MTTT algorithm to STTT using archived samples from LD patients or control subjects. In a prospective phase, we used the same algorithms to analyze consecutive excess samples submitted for routine LD serology to three clinical laboratories. For the retrospective phase, MTTTs 1 and 2 were more sensitive (56% and 74%) than STTT (41%; P ≤ 0.03) among 61 patients with acute erythema migrans (EM). In LD patients with neuroborreliosis, carditis, or arthritis (n = 75), sensitivity was comparable between algorithms (96 to 100%; P = 1.0). Among 190 control subjects without past LD, all algorithms were highly and comparably specific (≥99%, P = 0.48). For the prospective phase, (n = 2,932), positive percent-agreement (PPA), negative percent-agreement (NPA), and overall agreement of MTTT 1 with STTT were 93%, 97.7% and 97.4% (kappa 0.80). MTTT 2 yielded higher PPA (98%) but lower NPA (96.1%) and overall agreement (96.2%, kappa 0.74; all P < 0.05). Compared with STTT, both MTTT algorithms provided increased sensitivity in EM patients, comparable sensitivity in later disease and non-inferior specificity.Modified two-tiered testing (MTTT) algorithms for Lyme disease (LD), which involve the sequential use of orthogonal enzyme immunoassays (EIAs) without immunoblotting, are acceptable alternatives to standard two-tiered testing (STTT; EIA followed by immunoblots) provided the EIAs have been FDA-cleared for this intended use. We evaluated four Zeus Scientific LD EIAs used in two distinct MTTT algorithms for FDA review. MTTT 1 used a VlsE1/pepC10 polyvalent EIA followed by a whole-cell sonicate (WCS) polyvalent EIA. MTTT 2 used the same first-tier EIA followed by separate IgM and IgG WCS EIAs. In a retrospective phase, we compared each MTTT algorithm to STTT using archived samples from LD patients or control subjects. In a prospective phase, we used the same algorithms to analyze consecutive excess samples submitted for routine LD serology to three clinical laboratories. For the retrospective phase, MTTTs 1 and 2 were more sensitive (56% and 74%) than STTT (41%; P ≤ 0.03) among 61 patients with acute erythema migrans (EM). In LD patients with neuroborreliosis, carditis, or arthritis (n = 75), sensitivity was comparable between algorithms (96 to 100%; P = 1.0). Among 190 control subjects without past LD, all algorithms were highly and comparably specific (≥99%, P = 0.48). For the prospective phase, (n = 2,932), positive percent-agreement (PPA), negative percent-agreement (NPA), and overall agreement of MTTT 1 with STTT were 93%, 97.7% and 97.4% (kappa 0.80). MTTT 2 yielded higher PPA (98%) but lower NPA (96.1%) and overall agreement (96.2%, kappa 0.74; all P < 0.05). Compared with STTT, both MTTT algorithms provided increased sensitivity in EM patients, comparable sensitivity in later disease and non-inferior specificity.
Author Sfeir, Maroun M
Branda, John A
Granger, Dane
Steere, Allen C
Fritsche, Thomas R
Theel, Elitza S
Meece, Jennifer K
Author_xml – sequence: 1
  givenname: Maroun M
  surname: Sfeir
  fullname: Sfeir, Maroun M
  organization: UConn Health, Farmington, Connecticut, USA
– sequence: 2
  givenname: Jennifer K
  surname: Meece
  fullname: Meece, Jennifer K
  organization: Marshfield Clinicgrid.280718.4 Health System, Marshfield, Wisconsin, USA
– sequence: 3
  givenname: Elitza S
  orcidid: 0000-0002-6886-2294
  surname: Theel
  fullname: Theel, Elitza S
  organization: Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA
– sequence: 4
  givenname: Dane
  surname: Granger
  fullname: Granger, Dane
  organization: Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinicgrid.66875.3a, Rochester, Minnesota, USA
– sequence: 5
  givenname: Thomas R
  surname: Fritsche
  fullname: Fritsche, Thomas R
  organization: Marshfield Clinicgrid.280718.4 Health System, Marshfield, Wisconsin, USA
– sequence: 6
  givenname: Allen C
  surname: Steere
  fullname: Steere, Allen C
  organization: Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
– sequence: 7
  givenname: John A
  orcidid: 0000-0002-6929-1219
  surname: Branda
  fullname: Branda, John A
  organization: Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35418241$$D View this record in MEDLINE/PubMed
BookMark eNpNkD1PwzAYhC1URD9gY0YeWVJix06csQrlQ2rFQCshlsh1XhdXdlziBNSVX04qQGK6ZzjdnW6MBrWvAaFLEk8JoeJmp9w0ppyKiJITNCJxLqI0jV8G_3iIxiHs4pgwxvkZGiacEUEZGaGvZWdbo6BuocGFNbVR0uL5h7SdbI2vsdd46SujDVR49emjlYHmiBBaU2_xzG59Y9o3F7D2DV4cHOBbE0AGwOtwdLxCF_CzMn1Fn6Jw4Z2DRpm-ZhaCPIRzdKqlDXDxqxO0vpuviodo8XT_WMwWkezHtlEOOskTTTQTWuScqZRCxlJaaRnLNAHGtcoZZwKSTG20yPKeYKN5ledaJjGdoOuf3H3j37t-f-lMUGCtrMF3oaQp739MSJb11qtfa7dxUJX7xjjZHMq_3-g3sthy-A
CitedBy_id crossref_primary_10_1097_INF_0000000000004304
crossref_primary_10_1128_jcm_00139_24
crossref_primary_10_1055_a_2140_9866
crossref_primary_10_1093_cid_ciae104
crossref_primary_10_3390_pathogens12111282
crossref_primary_10_1093_infdis_jiae229
crossref_primary_10_1371_journal_pone_0327376
crossref_primary_10_1093_ajcp_aqae112
crossref_primary_10_1128_jcm_00807_23
crossref_primary_10_1016_j_diagmicrobio_2022_115837
crossref_primary_10_1128_jcm_00483_25
crossref_primary_10_1093_jalm_jfac047
crossref_primary_10_1093_jalm_jfae127
crossref_primary_10_1089_vbz_2024_0043
crossref_primary_10_1007_s10096_024_04956_y
crossref_primary_10_3390_pathogens13050353
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1128/jcm.02528-21
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
Biology
EISSN 1098-660X
ExternalDocumentID 35418241
Genre Multicenter Study
Journal Article
GrantInformation_xml – fundername: Zeus Scientific
GroupedDBID ---
.55
0R~
18M
29K
2WC
39C
4.4
53G
5GY
5RE
5VS
AAGFI
ABOCM
ABPPZ
ACGFO
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
CGR
CS3
CUY
CVF
D-I
DIK
DU5
E3Z
EBS
ECM
EIF
F5P
FRP
GX1
H13
HYE
HZ~
KQ8
L7B
NPM
O9-
OK1
P2P
P6G
RHI
RNS
RPM
RSF
TR2
W8F
WOQ
X7M
ZCA
~KM
7X8
ID FETCH-LOGICAL-a418t-9ef393f1f48f8954c62e7462dfa0a63e45fc94548e37cbf8798e3ebf5d99fa302
IEDL.DBID 7X8
ISICitedReferencesCount 16
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000783235800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1098-660X
IngestDate Fri Sep 05 09:59:09 EDT 2025
Tue Sep 30 00:37:53 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Lyme disease
Borrelia burgdorferi
diagnostics
Borrelia
immunodiagnostics
serology
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a418t-9ef393f1f48f8954c62e7462dfa0a63e45fc94548e37cbf8798e3ebf5d99fa302
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-6886-2294
0000-0002-6929-1219
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/9116174
PMID 35418241
PQID 2650253177
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2650253177
pubmed_primary_35418241
PublicationCentury 2000
PublicationDate 2022-05-18
PublicationDateYYYYMMDD 2022-05-18
PublicationDate_xml – month: 05
  year: 2022
  text: 2022-05-18
  day: 18
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Journal of clinical microbiology
PublicationTitleAlternate J Clin Microbiol
PublicationYear 2022
SSID ssj0014455
Score 2.4714267
Snippet Modified two-tiered testing (MTTT) algorithms for Lyme disease (LD), which involve the sequential use of orthogonal enzyme immunoassays (EIAs) without...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage e0252821
SubjectTerms Algorithms
Animals
Antibodies, Bacterial
Borrelia burgdorferi
Fishes
Humans
Immunoglobulin M
Lyme Disease
Prospective Studies
Retrospective Studies
Sensitivity and Specificity
Serologic Tests
Title Multicenter Clinical Evaluation of Modified Two-Tiered Testing Algorithms for Lyme Disease Using Zeus Scientific Commercial Assays
URI https://www.ncbi.nlm.nih.gov/pubmed/35418241
https://www.proquest.com/docview/2650253177
Volume 60
WOSCitedRecordID wos000783235800001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JTsMwELXYxYV9KZuMxNWQ2E5in1DFIg606qGgikvlOHYpogk0LahXvpxxktITEhKXKIcslj2ZPHnevIfQmdJCc2sMocqLCYeLiEx8RUSccN9TXJc624_3UbMpOh3Zqjbc8opWOc2JRaJOMu32yC8oQAkKARNFl2_vxLlGuepqZaExjxYZQBlH6Yo6syoC54Xrqe80M8PQ60yJ71RcvOjBOTyPQpj4v4PL4idzu_7f4W2gtQpe4noZD5tozqRbaLk0nJxsoZVGVUrfRl9F663jZpohrtRBX_HNj_g3zixuZEnfAkbF7c-MtPvO1hO3nSxH2sP11x68f_Q8yDHgXnw_GRh8XVZ7cMFDwE9mnOMidxR8JOx6UZy_kxtfnqtJvoMebm_aV3ekMmQgivtiRKSxTDLrWy6skAHXITURD2liladCZnhgtYTFFYZFOrYiknBmYhskUlrFPLqLFtIsNfsIh4onMtGcW4fYYoeKIDiUb7j2mbCshk6n89yFgHdVDJWabJx3ZzNdQ3vlYnXfSmWOLgtgnIBJDv5w9yFapa6VwSmxiiO0aOFzN8doSX-M-vnwpIgkODZbjW-QZ9WG
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Multicenter+Clinical+Evaluation+of+Modified+Two-Tiered+Testing+Algorithms+for+Lyme+Disease+Using+Zeus+Scientific+Commercial+Assays&rft.jtitle=Journal+of+clinical+microbiology&rft.au=Sfeir%2C+Maroun+M&rft.au=Meece%2C+Jennifer+K&rft.au=Theel%2C+Elitza+S&rft.au=Granger%2C+Dane&rft.date=2022-05-18&rft.eissn=1098-660X&rft.volume=60&rft.issue=5&rft.spage=e0252821&rft_id=info:doi/10.1128%2Fjcm.02528-21&rft_id=info%3Apmid%2F35418241&rft_id=info%3Apmid%2F35418241&rft.externalDocID=35418241
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-660X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-660X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-660X&client=summon